CD4 and melanoma: Tsuji et al. has shown that DR01-restricted CD4+ T cell lines specific for the NY-ESO-195–106 epitope were able to respond to un-manipulated melanoma cell lines, while CD4+ T cells specific to NY-ESO-187–98 could not (35).